Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of <i>DPYD</i> Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study

• Main Authors: Xando Díaz-Villamarín (Author), María Martínez-Pérez (Author), María Teresa Nieto-Sánchez (Author), Gabriela Ruiz-Tueros (Author), Emilio Fernández-Varón (Author), Alicia Torres-García (Author), Beatriz González Astorga (Author), Isabel Blancas (Author), Antonio J. Iáñez (Author), José Cabeza-Barrera (Author), Rocío Morón (Author)
• Format: Book
• Published: MDPI AG, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fluoropyrimidines (FPs) are commonly prescribed in many cancer streams. The EMA and FDA-approved drug labels for FPs recommend genotyping the <i>DPYD</i>*2A (rs3918290), *13 (rs55886062), *HapB3 (rs56038477), alleles, and <i>DPYD</i> rs67376798 before treatment starts. We imp...